ES2194273T3 - Regulacion de la produccion de inmunoglobulinas por la interleucina-9. - Google Patents

Regulacion de la produccion de inmunoglobulinas por la interleucina-9.

Info

Publication number
ES2194273T3
ES2194273T3 ES98200841T ES98200841T ES2194273T3 ES 2194273 T3 ES2194273 T3 ES 2194273T3 ES 98200841 T ES98200841 T ES 98200841T ES 98200841 T ES98200841 T ES 98200841T ES 2194273 T3 ES2194273 T3 ES 2194273T3
Authority
ES
Spain
Prior art keywords
production
interleukin
interleucine
regulation
immunoglobulin production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98200841T
Other languages
English (en)
Inventor
Bernard Dugas
Catherine Druez
Pierre Braquet
Catherine Uyttenhove
Snick Charles Van
Jean-Michel Mencia-Huerta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ipsen Pharma SAS
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2194273T3 publication Critical patent/ES2194273T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE ENSE¿A UN PROCEDIMIENTO PARA INHIBIR LA PRODUCCION DE IGE, Y UN PROCEDIMIENTO PARA AUMENTAR LA PRODUCCION DE IGG. LOS PROCEDIMIENTOS ESTAN UNIDOS AL PAPEL DE LA INTERLEUQUINA-9 EN LA PRODUCCION DE ANTICUERPOS. ESPECIFICAMENTE, SE POTENCIA LA PRODUCCION DE IGG ADMINISTRANDO BIEN A UN SUJETO, BIEN A UN CULTIVO DE CELULAS, UNA COMBINACION DE INTERLEUQUINA-4 E INTERLEUQUINA-9. SE INHIBE LA PRODUCCION DE IGE, ADMINISTRANDO UNA CANTIDAD DE UN INHIBIDOR DE INTERLEUQUINA-9 A UN SUJETO.
ES98200841T 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9. Expired - Lifetime ES2194273T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/593,238 US5132109A (en) 1990-10-05 1990-10-05 Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof

Publications (1)

Publication Number Publication Date
ES2194273T3 true ES2194273T3 (es) 2003-11-16

Family

ID=24373963

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91918691T Expired - Lifetime ES2136065T3 (es) 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9.
ES98200841T Expired - Lifetime ES2194273T3 (es) 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES91918691T Expired - Lifetime ES2136065T3 (es) 1990-10-05 1991-10-01 Regulacion de la produccion de inmunoglobulinas por la interleucina-9.

Country Status (11)

Country Link
US (1) US5132109A (es)
EP (2) EP0553198B1 (es)
JP (2) JP3205754B2 (es)
AT (2) ATE182079T1 (es)
AU (2) AU646509B2 (es)
CA (1) CA2093434C (es)
DE (2) DE69133225T2 (es)
DK (2) DK0553198T3 (es)
ES (2) ES2136065T3 (es)
GR (1) GR3031518T3 (es)
WO (1) WO1992005698A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69321720T2 (de) * 1992-03-09 1999-05-06 Ludwig Inst Cancer Res Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
US6911887B1 (en) 1994-09-12 2005-06-28 Matsushita Electric Industrial Co., Ltd. Inductor and method for producing the same
CA2230240C (en) * 1995-08-24 2009-08-18 Magainin Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
ZA967182B (en) 1995-08-24 1998-05-25 Magainin Pharma Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
AU2007202406B2 (en) * 1995-08-24 2010-08-12 Ligand Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
EP1471144B1 (en) * 1996-12-02 2010-06-23 Genaera Corporation Biological variability of asthma associated factor AAF2 (IL-9 receptor) useful in treating and diagnosing atopic allergies including asthma and related disorders
WO1998024904A2 (en) * 1996-12-02 1998-06-11 Magainin Pharmaceuticals Inc. Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
US20040219149A1 (en) * 2001-06-08 2004-11-04 Yuhong Zhou Methods for the modulation of il-13
JP4270974B2 (ja) 2003-08-04 2009-06-03 本田技研工業株式会社 車両における燃料タンクの配置構造
US20100219541A1 (en) 2007-09-28 2010-09-02 Konica Minolta Opto, Inc. Method for manufacturing optical device
CN101970198B (zh) 2008-03-19 2013-05-29 柯尼卡美能达精密光学株式会社 晶片透镜的制造方法
EP2759395A1 (en) 2008-03-19 2014-07-30 Konica Minolta Opto, Inc. Method for producing a wafer lens
EP2752687A1 (en) 2010-04-27 2014-07-09 Konica Minolta Opto, Inc. Image capture lens, wafer lens, wafer lens laminate, method of manufacturing image capture lens, image capture lens intermediate product, method of manufacturing image capture lens intermediate product
US9828087B2 (en) * 2016-01-27 2017-11-28 Honeywell International Inc. Systems and methods for ground effect ceiling limit display

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US511951A (en) * 1894-01-02 Chusetts
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
WO1991014767A1 (en) * 1990-03-23 1991-10-03 Ludwig Institute For Cancer Research Method for enhanced growth and proliferation of mast cells

Also Published As

Publication number Publication date
ES2136065T3 (es) 1999-11-16
AU646509B2 (en) 1994-02-24
AU8760791A (en) 1992-04-28
DE69133225D1 (de) 2003-04-24
DE69131450D1 (de) 1999-08-19
DK0553198T3 (da) 1999-12-27
JP2001253835A (ja) 2001-09-18
AU5243493A (en) 1994-02-17
US5132109A (en) 1992-07-21
DK0903150T3 (da) 2003-07-21
DE69131450T2 (de) 2000-03-30
EP0553198B1 (en) 1999-07-14
WO1992005698A1 (en) 1992-04-16
GR3031518T3 (en) 2000-01-31
EP0553198A4 (en) 1994-08-17
EP0903150A1 (en) 1999-03-24
CA2093434C (en) 1999-08-10
AU656493B2 (en) 1995-02-02
ATE182079T1 (de) 1999-07-15
JP3205754B2 (ja) 2001-09-04
JPH06502404A (ja) 1994-03-17
DE69133225T2 (de) 2004-02-19
ATE234632T1 (de) 2003-04-15
EP0553198A1 (en) 1993-08-04
EP0903150B1 (en) 2003-03-19
CA2093434A1 (en) 1992-04-06

Similar Documents

Publication Publication Date Title
ES2136065T3 (es) Regulacion de la produccion de inmunoglobulinas por la interleucina-9.
DK0497706T3 (da) Termoformbar komposition, fremgangsmåde til fremstilling heraf samt anvendelse heraf med henblik på at opnå termoformede emner
ES2182897T3 (es) Regulacion por proteasoma de la actividad de nf-kappa-b.
ES2058490T3 (es) Metodo de reducir respuestas de inmunoglobulina e.
ES2070820T3 (es) Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
DE59309740D1 (de) Lyopilisierte, wirkstoffhaltige emulsion
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
PT640608E (pt) Intermediarios na sintese de cefalosporinas
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DE3862547D1 (de) Vorrichtung zur anaeroben behandlung von biomasse.
ATE41927T1 (de) Phenylalkylamine - bioregulatoren.
DK447784D0 (da) Immuninterferon
DE69124317T2 (de) Monoklonale Antikörper gegen Leptosphaeria
IT1229123B (it) Tracciante per prodotti petroliferi
GB8811342D0 (en) Expression of antibody heavy & light chain variable domains as active hetero-dimer in myeloma cells
IT1178489B (it) Vettore clonante, procedimento per la sua costruzione e procedimento di concentrazione e di purificazione di proteine prodotte, formate dal vettore clonante
SU1692146A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o
SE8501740D0 (sv) Klammer med inverterat t-tversnitt